Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yes Sleepy I think its this bit.
Phase 3A Validation is currently undertaken at PHE Porton Down. During the duration of the DPS, DHSC may identify another regime(s), whether or not undertaken at PHE Porton Down, that may or shall be used to achieve the same objective in which event “Phase 3A Validation” shall, for the purposes of this Specification, the DPS Information Document, and any Application, mean validation by such regime.
The same wording is used also in the Phase VOC section.
Sorry Im not sure where to find the file, I have it saved as Specification for DPS.
Hahahaha feck me sure why not £2.50 - 2.70 like Avacta or better still £7 like Ncyt, unbelievable stupidity.
Like pulluing nails mate hmrc and those two.
Dont know if it relates to you Matt but I got an email today from vitaltax who provide a plugin for excel to allow MTD vat returns.
They said MTD vat service was down and they would notify when operational again.
VC What are you on about I havnt even commented on your Zika post, I think its pointless.
How is the S&S figures misreported when stating CT value, we a know how CTvalues and S&S work, if anything it shows honesty to state the CT values.
Come to think of it did Mologic ever state their CT values?
Vc you have suggested it will take a year to produce a new LFT for varients (which may never be required) and that has been correctly countered as complete nonsense.
You have also shown a complete lack of understanding of Avactas Precision platform and their TMAC drug conjugates.
The only proven toxicity here is yourself.
What a crock of **** you tool.
"This is why the immune system is conditioned to receive antibody treatment and is why Avacta purchased pre|CISION and is trailing it for the eventual purpose of conditioning the immune system to enable lead Affimer PD-L1 Affimer to be used for chemotherapies and tumour treatment. This really is basics"
The lead affimer is not used for chemotherapies that is the work of the seperate PreCision platform.
I think Matt meant CV as it is possible to obtain Phase 3A PD validation via other regimes, such as the Clinical validation that is currently being carried out by Avacta.
Also tellingly the same spec document states preference for Anterior Nasal sampling, a requirement for asymptomatic testing, and the word affimer also crops up.
Im not saying it will be Avactas but it might be, tbh Im not fussed I dont believe Avactas success will be determined by involvement in a Sovereign test.
Missed all the fun today again just like to add that although it would be nice to be the involved in the "Sovereign test" it wont be the end if we are not.
We dont need £100s millions at this stage to make this company (we might and I will be over the moon), all we need here is to pull in enough revenues to carry forward the huge pipeline of NEAR TERM chemo prodrugs in the pipeline.
AVACTA have been building to this point with PreCision and TMAC for several years and I feel extremely fortunate to have got involved at this stage.
Many including myself initially jumped onto this as a covid play but now realize the real potential wealth creation was already here, some still dont get it, but many astute do.
I challenge anyone to name a share with better short, medium and long term potential.
"Im afraid you’re talking complete ****e there okenhurst. "
"Nope... he's right. DHSC says CE/UKCA marking and then evaluation by PHE Porton Down if the test is to be included in the sovereign test programme: https://www.gov.uk/guidance/lateral-flow-validation-prioritisation-criteria-for-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens"
Make of this what you will.
During the duration of the DPS, DHSC may identify another regime(s), whether or not undertaken at PHE Porton Down, that may or shall be used to achieve the same objective in which event “Phase 3A Validation” shall, for the purposes of this Specification, the DPS Information Document, and any Application, mean validation by such regime.
Hmm I was a concerned holder too, so much so that I sold out 55k of ODX shares at their recent high to top up here at 180p
All the same im sure ODX will sell enough tests to maintain their current mcap over the next year or two.
Meanwhile in Avactalnd the multiple multi billion opportunities will be landing left, right and center :)